Institute For Wealth Management, Llc. Fibrogen Inc Transaction History

Institute For Wealth Management, Llc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 20, 2023	SELL	$15.95 - $25.18 $91,281 - $144,105	-5,723 Reduced 21.71%	20,642 $385,000
Q4 2022 Feb 02, 2023	SELL	$13.27 - $17.73 $13,216 - $17,659	-996 Reduced 3.64%	26,365 $422,000
Q3 2022 Oct 18, 2022	BUY	$11.4 - $14.6 $7,626 - $9,767	669 Added 2.51%	27,361 $356,000
Q2 2022 Jul 25, 2022	BUY	$7.94 - $12.96 $35,610 - $58,125	4,485 Added 20.2%	26,692 $282,000
Q1 2022 Apr 29, 2022	BUY	$12.02 - $16.79 $29,388 - $41,051	2,445 Added 12.37%	22,207 $267,000
Q4 2021 Jan 21, 2022	BUY	$9.93 - $15.39 $52,629 - $81,567	5,300 Added 36.65%	19,762 $279,000
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $147,223 - $385,267	14,462 New	14,462 $148,000
Q2 2019 Aug 02, 2019	SELL	$35.13 - $55.53 $151,059 - $238,779	-4,300 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$42.83 - $59.91 $184,169 - $257,612	4,300 New	4,300 $234,000
Q1 2018 May 15, 2018	SELL	$45.35 - $61.65 $195,005 - $265,095	-4,300 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$41.95 - $60.1 $180,385 - $258,430	4,300	4,300 $204,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Institute For Wealth Management, Llc., based on Form 13F filings with the SEC.

Stay updated on Institute For Wealth Management, Llc. with notifications on news.